Skip to main content
NCBI home page
Iranian Journal of Pharmaceutical Research : IJPR logoLink to Iranian Journal of Pharmaceutical Research : IJPR
. 2019 Autumn;18(4):1816–1822. doi: 10.22037/ijpr.2019.14547.12476

Novel 5-(nitrothiophene-2-yl)-1,3,4-Thiadiazole Derivatives: Synthesis and Antileishmanial Activity against promastigote stage of Leishmania major

Seyed Esmail Sadat-Ebrahimi a, Maryam Mirmohammadi a, Zahra Mojallal Tabatabaei b, Marjan Azimzadeh Arani c, Sogol Jafari-Ashtiani a, Mahsa Hashemian a, Parham Foroumadi a, Azadeh Yahya-Meymandi a, Setareh Moghimi c, Mohammad Hassan Moshafi d, Peiman Norouzi a, Susan Kabudanian Ardestani b, Alireza Foroumadi a,c,*
PMCID: PMC7059068  PMID: 32184848

Abstract

In this study, a series of novel compounds based on 5-(5-nitrothiophene-2-yl)-1,3,4-thiadiazole possessing (het) aryl thio pendant at C-2 position of thiadiazole ring is developed and evaluated as antileishmanial agents using MTT colorimetric assay. 10 New compounds containing aryl and heteroaryl derivatives, started from thiophene-2-carbaldehyde in five steps, were synthesized in good to excellent yields and characterized by 1H-NMR, 13C-NMR, and IR spectroscopy. Through the compounds 6a-j, methylimidazole containing derivative 6e was recognized as the most active compound against L. major promastigotes exhibiting IC50 values of 11.2µg/mL and 7.1µg/mL after 24 and 48 h, respectively. This compound is > 4 fold more effective than Glucantime as a standard drug (IC50 = 50 µg/mL after 24 h and 25 µg/mL after 48 h).

Key Words: Leishmaniasis, Promastigote, 1, 3, 4-thiadiazole, MTT assay, Synthesis

Introduction

Leishmaniasis, a neglected tropical disease (NTD), is defined as the array of vector-born infections, caused by protozoans of the genus leishmania. The leishmania parasites are transmitted to humans by the bite of female phlebotomine sandflies (1-3).

Leishmaniasis is one of the world’s health problems, causes considerable morbidity, which could be fatal when untreated. According to WHO data, this parasitic disease affects about 350 million people in 88 countries and two million new cases occur yearly (4). Several clinical manifestations are categorized in terms of leishmaniasis. The three main forms are: visceral leishmaniasis, cutaneous leishmaniasis, and muco-cutaneous leishmaniasis (5-7).

Despite great efforts in leishmaniasis treatment, some deficiencies in control programs still need to be made over. No functional vaccine to prevent any form of leishmaniasis has not proved itself and the conventional drugs, including sodium stibogluconate (pentostam) and meglumine antimonate (glucantime) used since 1940 as the linchpins of antileishmanial therapy, exhibit the disadvantages of high toxicity, long half-life, possible therapeutic failure, and unaffordable costs. Therefore, there is a strong demand to find new, safe, and inexpensive potent compounds (8-13).

The nitroheterocycles such as nitrothiophene and nitrofuran have occupied a special place in medicinal chemistry with antiprotozoal and antibacterial properties (14-15). Moreover, lots of 2,5-disubstituted-1,3,4-thiadiazole derivatives have been considerably evaluated in the treatment of leishmaniasis and the results revealed a significant inhibitory activity against leishmaniasis, depending upon the type and position of heterocyclic substituent on thiadiazole ring. It is worth mentioning that among the thiadiazoles with impressive bioactivities, those having a nitroheterocycle nucleus attached to a thiadiazole system have demonstrated unique antiparasitic and antimicrobial activity (16-27).

Considering the pharmacological importance of thiadiazoles and as a part of our continuous efforts pointed out the significance of 2,5-disubstituted-1,3,4-thiadiazole derivatives as anti-parasitic agents, we decided to report the synthesis of new 5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazoles possessing (het) arylthio substituents at C-2 position of thiadiazole ring to assess their antileishmanial activity against the promastigote form of Leishmania major.

Experimental

Chemistry

All the chemicals were obtained from Merck (Germany). Melting point was determined on a Kofler hot stage apparatus (C. Reichert, Vienna, Austria) and uncorrected. The IR spectra were recorded on a shimadzu 470 spectrophotometer, (KBr disks). The 1H and 13C NMR spectra were measured using Bruker 500 and 125 MHz spectrometer. All NMR samples were run in DMSO solvent and chemical shifts are expressed as parts per million with Me4Si as the internal standard. The mass spectra were run on an Agilent 5973 mass spectrometer at 70 eV.

General procedure for the synthesis of compounds 6a-j

To a solution of 2-chloro-5-(5-nitrothiophene-2-yl) 1,3,4-thiadiazole 5a-j (1.0 mmol) and K2CO3 (1.0 mmol) in DMF (7 mL), thiol derivatives (1.2 mmol) were added and the reaction mixture was stirred at 60 °C for 4-5 h. Then, the reaction was allowed to stir at room temperature overnight. The progress of the reaction was monitored by TLC, using petroleum ether/EtOAc as the mobile phase. After completion of the reaction, water (2 mL) was added and the precipitate was filtered off, washed with water and recrystallized with ethanol to give compounds 6a-j.

2-(5-Nitrothiophen-2-yl)-5-(phenylthio)-1,3,4-thiadiazole (6a). Yield: (71%). m.p. 147-149 °C. IR (KBr, cm–1): ν = 1512, 1413, 1347, 1326, 1080, 828, 745. 1H NMR (500 MHz, DMSO-d6): δ = 7.57-7.61 (m, 3H), 7.80-7.82 (m, 3H), 8.16 (d, J = 4.5 Hz, 1H) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 129.4, 129.7, 130.3, 130.4, 130.5, 134.2, 137.3, 160.5, 167.2, 170.7 ppm.

2-(p-Tolylthio)-5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazole (6b). Yield: (81%). m.p. 168-169 °C. -IR (KBr, cm–1): ν = 1509, 1492, 1467, 1347, 1373, 1081, 814, 729. 1H NMR (500 MHz, DMSO-d6): δ = 2.39 (s, 3H), 7.39 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.80 (d, J = 4.5 Hz, 1H), 8.14 (d, J = 4.5 Hz, 1H) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 20.8, 125.8, 130.2, 130.4, 130.5, 131.1, 131.3, 134.4, 137.3, 141.3, 160.2 ppm. MS (m/z, %): 335 (M+, 98), 154 (68), 123 (44), 105 (100), 91 (66), 65 (40), 45 (37).

2-(4-Chlorophenylthio)-5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazole (6c). Yield: 0.26 g (73%). m.p. 180-182 °C. IR (KBr, cm–1): ν = 1508, 1475, 1420, 1371, 1346, 1081, 828. 1H NMR (500 MHz, CDCl3): δ = 7.28 (d, J = 4.0 Hz, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.86 (d, J = 4.0 Hz, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ = 112.5, 113.1, 122.9, 124.0, 130.7, 135.8, 145.7 (2C), 153.2, 164.9 ppm.

2-(4-Bromophenylthio)-5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazole (6d). Yield: (65%). m.p. 181-183 °C. IR (KBr, cm–1): ν = 1507, 1469, 1420, 1373, 1264, 1011, 824. 1H NMR (500 MHz, CDCl3): δ = 7.28 (d, J = 4.5 Hz, 1H), 7.58 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 7.86 (d, J = 4.5 Hz, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ = 112.5, 113.1, 122.5, 124.8, 133.7, 135.9, 145.0, 152.7, 159.0, 162.0.

2-(1-Methyl-1H-imidazol-2-ylthio)-5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazole (6e). Yield: (70%). m.p. 173-175 °C. IR (KBr, cm–1): ν = 1543, 1461, 1411, 1339, 1281, 1225, 730. 1H NMR (500 MHz, DMSO-d6): δ = 3.76 (s, 3H), 7.22 (s, 1H), 7.59 (s, 1H), 7.86 (d, J = 5.5 Hz, 1H), 8.17 (d, J = 5.5 Hz, 1H) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 126.3, 129.6, 130.4, 130.5, 131.3, 137.2, 152.1, 161.3, 167.8 ppm.

2-(4,5-Dihydrothiazol-2-ylthio)-5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazole (6f). Yield: (78%). m.p. 249-250 °C. IR (KBr, cm–1): ν = 1500, 1449, 1416, 1382, 1344, 1266, 1070, 820. 1H NMR (500 MHz, DMSO-d6): δ = 3.73 (t, J = 8.0 Hz, 2H), 5.04 (t, J = 8.0 Hz, 2H), 7.91 (d, J = 4.0 Hz, 1H), 7.20 (d, J = 4.0 Hz, 1H) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 28.2, 58.1, 125.2, 131.5, 134.0, 139.1, 151.4, 157.6, 163.2 ppm.

2-(5-(5-Nitrothiophen-2-yl)-1,3,4-thiadiazol-2-ylthio)-1H-benzo[d]imidazole (6g). Yield: (70%). m.p. 223-225 °C. IR (KBr, cm–1): ν = 1504, 1462, 1361, 1265, 729. 1H NMR (500 MHz, DMSO-d6): δ = 7.28-7.31 (m, 2H), 7.61-7.63 (m, 2H), 7.94 (d, J = 4.5 Hz, 1H), 8.20 (d, J = 4.5 Hz, 1H), 13.02 (m, NH) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 114.4, 114.5, 115.1, 122.0, 122.7, 122.9, 123.6, 139.1, 141.7, 145.7, 152.2, 157.6, 163.2 ppm.

2-(5-(5-Nitrothiophen-2-yl)-1,3,4-thiadiazol-2-ylthio)-6-chloro-1H-benzo[d]imidazole (6h). Yield: (70%). m.p. 243-245 °C. IR (KBr, cm–1): ν = 1507, 1435, 1361, 1335, 1235, 810, 729. 1H NMR (500 MHz, DMSO-d6): δ = 7.30 (dd, J = 8.5, 1.5 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 1.5 Hz, 1H), 7.94 (d, J = 4.5 Hz, 1H), 8.20 (d, J = 4.5 Hz, 1H) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 114.4, 114.5, 115.2, 123.1, 123.3, 127.4, 137.6, 143.6, 145.6 (2C), 152.3, 158.0, 162.5 ppm. MS (m/z, %): 397 (M+2, 45), 395(M+, 100), 319 (69), 241 (12), 183 (49), 156 (35), 124 (21).

2-(5-(5-Nitrothiophen-2-yl)-1,3,4-thiadiazol-2-ylthio)benzo[d]oxazole (6i). Yield: (75%). m.p. 196-198 °C. IR (KBr, cm–1): ν =1500, 1449, 1416, 1344, 1316, 1266, 1071, 820. 1H NMR (500 MHz, DMSO-d6): δ = 7.44-7.49 (m, 2H), 7.79 (d, J = 7.0 Hz, 2H), 8.04 (d, J = 4.5 Hz, 1H), 8.24 (d, J = 4.5 Hz, 1H) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 125.5, 125.9, 126.2, 130.4, 130.5, 130.9, 131.1, 136.7, 140.6, 151.6, 157.3, 159.0, 163.9 ppm.

2-(5-(5-Nitrothiophen-2-yl)-1,3,4-thiadiazol-2-ylthio)benzo[d]thiazole (6j). Yield: (68%). m.p. 215-217 °C. IR (KBr, cm–1): ν = 1509, 1411, 1338, 1258, 1066, 761, 729. 1H NMR (500 MHz, DMSO-d6): δ = 7.52 (t, J = 7.5 Hz, 1H), 7.60 (t, J = 7.5 Hz, 1H), 8.01 (d, J = 3.5 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 8.24 (d, J = 3.5 Hz, 1H) ppm.

In-vitro antileishmanial activity

Antileishmanial effects of compounds on promastigote were investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. All of the compounds were screened at two concentrations 10 and 20 μg/mL. The 50% inhibitory concentration (IC50) was calculated using various concentrations (1, 5, 10 and 20 μg/mL) of most active compound 6e, Log phase parasites (6 ×107 cells/mL) were incubated with compounds for 24 h at the room temperature. The positive and negative controls were Glucantime and DMSO as respectively. After 24 h, the media was removed and the cells were treated with MTT solution (5 mg/mL) for 4 h at 37 °C. Then, the cells were centrifuged for 15min at 2000 rpm and the pellets were dissolved in 100µL of DMSO and the absorbances were read in a microplate reader set at a wavelength of 492 nm.

Results and Discussion

Chemistry

The synthetic strategy to achieve target compounds 6a-j is outlined in Figure 1. The key intermediate compound 5 was obtained from thiophene-2-carboxaldehyde in four steps according to our previously reported synthetic method (28).

Figure1.

Figure1

Open in a new tab

Synthesis of compounds 6a-j. Reagents and conditions: (i) HNO3, AC2O, CH3COOH; (ii) thiosemicarbazide, EtOH, HCl, reflux; (iii) NH4Fe (SO4)2.12H2O, reflux; (iv) NaNO2, HCl, Cu; (v) Ar-SH, K2CO3, DMF, 60 °C

The reaction of 2-chloro-5-(5-nitrothiophene-2-yl)1,3,4-thiadiazole 5 with appropriate thiol derivatives in the presence of potassium carbonate in dimethyl formamide (DMF) at 60 °C afforded title compounds 6a-j in good yields.

Pharmacology

In our previous work, we studied some 5-(nitroaryl)-1,3,4- thiadiazoles bearing different side chains such as phenacylthio, benzoylethanethio, and benzylthio derivatives on C-2 position of thiadiazole (29), obtaining promising results. So, we intended to develop new 2-(het) arylthio-5-(nitrothiophen)-1,3,4-thiadiazole analogous in order to investigate the antileishmaniasis activity of the compounds with S-pendant groups. For this purpose, we synthesized and evaluated anti-parasitic activity of the title compounds 6a-j against leishmania promastigote using MTT assay.

The in-vitro anti-leishmania activities of the compounds were investigated at 10 and 20 µg/mL. The results are listed in Table 1. Compared to our previous findings, the observed weak inhibitory activities of the target compounds revealed the importance of alkyl linker in S-pendant groups.

Table1.

Structure and in-vitro inhibitory activities of compounds 6a-j against the promastigote form of L. major

graphic file with name ijpr-18-1816-g002.jpg
Open in a new tab

* IC50 for 6e: 11.2 µg/mL after 24 h and 7.1 µg/mL after 48 h,

IC50 for Glucantim: 50 µg/mL after 24 h and 25 µg/mL after 48 h.

Among the synthesized compounds, Benzimidazole containing derivative 6g was more active than the corresponding benzoxazole 6i and benzothiazole 6j analogues. Unsubstituted aryl derivatives exhibited better activity compared to the substituted ones. (Compound 6a versus 6b, 6c and 6d and compound 6g versus 6h).

Methyl-imidazole containing derivative 6e with IC50 = 11.2 µg/mL, after 24 h and 7.1 µg/mL after 48 h, shows the most potent activity in preventing the growth of promastigotes. This compound exhibits better performance in comparison to glucantime as a reference drug. The IC50 of glucantime was 50 µg/mL after 24 h and 25 µg/mL after 48 h. The inhibitory concentrations for 50% of inhibition (IC50) of parasitic growth after 24 and 48 h of the incubation were calculated based on a linear regression and reported as a mean.

Conclusion

In conclusion, a series of novel 5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazoles possessing (het) arylthio substituent at C-2 position of thiadiazole ring are synthesized and screened for inhibitory activity against promastigote form of L. major. Methyl-imidazolyl containing compound, 6e, was identified as the most potent compound against leishmaniasis which significantly reduced the viability of L. major promastigote.

Acknowledgment

This work was supported by grants from the Research Council of International Campus, Tehran University of Medical Sciences (Grant no.93-04-169-27094) and Iran′s National Elites Foundation (INEF). The authors declare that there is no conflict of interests.

References

  • 1.Nagill R, Kaur S. Vaccine candidates for leishmaniasis A review. Int. Immunopharmacol. 2011;11:1464–88. doi: 10.1016/j.intimp.2011.05.008. [DOI] [PubMed] [Google Scholar]
  • 2.Navarro M, Cisneros-Fajardo EJ, Fernandez-Mestre M, Arrieche D, Marchan E. Synthesis, characterization, DNA binding study and biological activity against Leishmania mexicana of [Cu (dppz)2] BF4. J. Inorg. Biochem. 2003;97:364–9. doi: 10.1016/s0162-0134(03)00290-3. [DOI] [PubMed] [Google Scholar]
  • 3.Hussain H, Al-Harrasi A, Al-Rawahi A, Green IR, Gibbons S. Fruitful decade for antileishmanial compounds from 2002 to late 2011. Chem. Rev. 2014;114:10369–428. doi: 10.1021/cr400552x. [DOI] [PubMed] [Google Scholar]
  • 4.WHO Research Priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis World Health Organ. Technol. Rep. Ser. 2012;975:1–100. [PubMed] [Google Scholar]
  • 5.Vannier-Santos MA, Martiny A, Souza WD. Cell biology of Leishmania spp: invading and evading. Curr. Pharm. 2002;8:297–318. doi: 10.2174/1381612023396230. [DOI] [PubMed] [Google Scholar]
  • 6.Sundar S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J. Med. Res. 2006;123:345–52. [PubMed] [Google Scholar]
  • 7.Ioset JR. Natural products for neglected diseases: a review. Curr. Org. Chem. 2008;12:643–66. [Google Scholar]
  • 8.Conti RV, Junior VL. Abordagem terapêutica da Leishmaniose Visceral no Brasil-revisão para clínicos. Med. Saúde Brasilia . 2015;4:240. [Google Scholar]
  • 9.Chávez-Fumagalli MA, Ribeiro TG, Castilho RO, Fernandes SO, Cardoso VN, Coelho CS, Mendonça DV, Soto M, Tavares CA, Faraco AA, Coelho EA. New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment. Rev. Soc. Bras. Med. Trop. . 2015;48:235–42. doi: 10.1590/0037-8682-0138-2015. [DOI] [PubMed] [Google Scholar]
  • 10.Micheletti AC, Beatriz A. Progressos recentes na pesquisa de compostos orgânicos com potencial atividade leishmanicida. Rev. Virtual Quim. 2012;4:268–86. [Google Scholar]
  • 11.Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect. Dis. 2007;7:581–96. doi: 10.1016/S1473-3099(07)70209-8. [DOI] [PubMed] [Google Scholar]
  • 12.Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr. Med. Chem. 2007;14:1153–69. doi: 10.2174/092986707780362862. [DOI] [PubMed] [Google Scholar]
  • 13.Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS. Med. 2006;3:162. doi: 10.1371/journal.pmed.0030162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Pires JR, Saito C, Gomes SL, Giesbrecht AM, Amaral AT. Investigation of 5-Nitrofuran Derivatives: Synthesis, Antibacterial Activity, and Quantitative Structure Activity Relationships. J. Med. Chem. 2001;44:3673–81. doi: 10.1021/jm0101693. [DOI] [PubMed] [Google Scholar]
  • 15.Muelas-Serrano S, Perez-Serrano J, Gómez-Barrio A, Arán V, Rodriguez-Caabeiro F. Ultrastructural alterations induced by nifurtimox and another nitro derivative on epimastigotes of Trypanosoma cruzi. Parasitol. Res. 2002;88:97–101. doi: 10.1007/s004360100497. [DOI] [PubMed] [Google Scholar]
  • 16.Poorrajab F, Ardestani SK, Foroumadi A, Emami S, Kariminia A, Behrouzi-Fardmoghadam M, Shafiee A. Selective leishmanicidal effect of 1, 3, 4-thiadiazole derivatives and possible mechanism of action against Leishmania species. Exp. Parasitol. 2009;121:323–30. doi: 10.1016/j.exppara.2008.12.004. [DOI] [PubMed] [Google Scholar]
  • 17.Tahghighi A, Marznaki FR, Kobarfard F, Dastmalchi S, Mojarrad JS, Razmi S, Ardestani SK, Emami S, Shafiee A, Foroumadi A. Synthesis and antileishmanial activity of novel 5-(5-nitrofuran-2-y1)-1,3,4-thiadiazoles with piperazinyl-linked benzamidine substituents. Eur. J. Med. Chem. 2011;46:2602–8. doi: 10.1016/j.ejmech.2011.03.053. [DOI] [PubMed] [Google Scholar]
  • 18.Rodrigues RF, da Silva EF, Echevarria A, Fajardo-Bonin R, Amaral VF, Leon LL, Canto-Cavalheiro MM. A comparative study of mesoionic compounds in Leishmania sp and toxicity evaluation. Eur. J. Med. Chem. 2007;42:1039–43. doi: 10.1016/j.ejmech.2006.12.026. [DOI] [PubMed] [Google Scholar]
  • 19.Tahghighi A, Razmi S, Mahdavi M, Foroumadi P, Ardestani SK, Emami S, Kobarfard F, Dastmalchi S, Shafiee A, Foroumadi A. Synthesis and anti-leishmanial activity of 5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazol-2-amines containing N-[(1-benzyl-1H-1, 2, 3-triazol-4-yl) methyl] moieties. Eur. J. Med. Chem. 2012;50:124–8. doi: 10.1016/j.ejmech.2012.01.046. [DOI] [PubMed] [Google Scholar]
  • 20.Tahghighi A, Emami S, Razmi S, Rezazade Marznaki F, Kabudanian Ardestani S, Dastmalchi S, Kobarfard F, Shafiee A, Foroumadi A. New 5-(nitroheteroaryl)-1, 3, 4-thiadiazols containing acyclic amines at C-2: synthesis and SAR study for their antileishmanial activity. J. Enzyme. Inhib. Med. Chem. 2013;28:843–52. doi: 10.3109/14756366.2012.689297. [DOI] [PubMed] [Google Scholar]
  • 21.Marznaki FR, Shakeri R, Ardestani SK, Tahghighi A, Foroumadi A. In-vitro immunobiological studies of novel 5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazoles with piperazinyl-linked benzamidine substituents against Leishmania major. Iran. J. Allergy Asthma Immunol. 2013;12:368–76. [PubMed] [Google Scholar]
  • 22.Foroumadi A, Soltani F, Moallemzadeh‐Haghighi H, Shafiee A. Synthesis in vitro‐Antimycobacterial Activity and Cytotoxicity of Some Alkyl α‐(5‐aryl‐1, 3, 4‐thiadiazole‐2‐ylthio)acetates. Arch. Pharm (Weinheim) 2005;338:112–6. doi: 10.1002/ardp.200400926. [DOI] [PubMed] [Google Scholar]
  • 23.Alipour E, Emami S, Yahya-Meymandi A, Nakhjiri M, Johari F, Ardestani SK, Poorrajab F, Hosseini M, Shafiee A, Foroumadi A. Synthesis and antileishmanial activity of 5-(5-nitroaryl)-2-substituted-thio-1, 3, 4-thiadiazoles. J. Enzyme. Inhib. Med. Chem. 2010;26:123–8. doi: 10.3109/14756361003733654. [DOI] [PubMed] [Google Scholar]
  • 24.Tahghighi A, Foroumadi A, Kabudanian-Ardestani S, Mahdian SM. Synthesis and comparison of in-vitro leishmanicidal activity of 5-(nitroheteroaryl)-1, 3, 4-thiadiazols containing cyclic amine of piperidin-4-ol at C-2 with acyclic amine analogues against Iranian strain of Leishmania major (MRHO/IR/75/ER) J. Arthropod Borne Dis. 2017;11:95–104. [PMC free article] [PubMed] [Google Scholar]
  • 25.Foroumadi A, Adibi H, Ardestani SK, Shirooie S, Bozorgomid A, Jafari A. Synthesis and Leishmanicidal Activity of 1-[5-(5-nitrofuran-2-yl)-1, 3, 4-thiadiazole-2-yl]-4-benzoylepiperazines. Iran. J. Pharm. Res. 2017;16:904–9. [PMC free article] [PubMed] [Google Scholar]
  • 26.Jain AK, Sharma S, Vaidya A, Ravichandran V, Agrawal RK. 1, 3, 4‐Thiadiazole and its Derivatives: A Review on Recent Progress in Biological Activities. Chem. Biol. Drug Des. 2013;81:557–76. doi: 10.1111/cbdd.12125. [DOI] [PubMed] [Google Scholar]
  • 27.Asadipour A, Edraki N, Nakhjiri M, Yahya-Meymandi A, Alipour E, Saniee P, Siavoshi F, Shafiee A, Foroumadi A. Anti-Helicobacter pylori activity and Structure-Activity Relationship study of 2-Alkylthio-5-(nitroaryl)-1,3,4-thiadiazole Derivatives. Iran. J. Pharm. Res. 2013;12:281–7. [PMC free article] [PubMed] [Google Scholar]
  • 28.Foroumadi A, Mansouri S, Kiani Z, Rahmani A. Synthesis and in-vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolones. Eur. J. Med. Chem. 2003;38:851–4. doi: 10.1016/s0223-5234(03)00148-x. [DOI] [PubMed] [Google Scholar]
  • 29.Alipour E, Emami S, Yahya-Meymandi A, Nakhjiri M, Johari F, Ardestani SK, Poorrajab F, Hosseini M, Shafiee A, Foroumadi A. Synthesis and antileishmanial activity of 5-(5-nitroaryl)-2-substituted-thio-1, 3, 4-thiadiazoles. J. Enzyme Inhib. Med. Chem. 2011;26:123–8. doi: 10.3109/14756361003733654. [DOI] [PubMed] [Google Scholar]

Articles from Iranian Journal of Pharmaceutical Research : IJPR are provided here courtesy of Brieflands

RESOURCES